It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Circulating microRNAs (miRNAs) in serum extracellular vesicles (EVs) are a promising biomarker in cancer. We aimed to elucidate the serum EVs miRNA biomarkers to identify patients with gallbladder cancer (GBC) and to clarify their potential roles. One hundred nineteen serum EVs from GBC and non-GBC individuals were isolated by pure-EVs-yieldable size-exclusion chromatography, and then were analyzed using a comprehensive miRNAs array and RT-qPCR-based validation. The functional roles of the identified miRNAs were also investigated using GBC cell lines. Serum EVs miR-1246 and miR-451a were significantly upregulated and downregulated, respectively in GBC patients (P = 0.005 and P = 0.001), in line with their expression levels in cancer tissue according to an in silico analysis. The combination of CEA and CA19-9 with miR-1246 showed the highest diagnostic power (AUC, 0.816; Sensitivity, 72.0%; Specificity, 90.8%), and miR-1246 was an independent prognostic marker of GBC (Hazard ratio, 3.05; P = 0.017) according to a Cox proportional hazards model. In vitro, miR-1246 promoted cell proliferation and invasion, while miR-451a inhibited cell proliferation and induced apoptosis with the targeting of MIF, PSMB8 and CDKN2D. Taken together, miR-1246 in serum EVs has potential application as a diagnostic and prognostic marker and miR-451a may be a novel therapeutic target in GBC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Department of Gastroenterology and Hepatology, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
2 Okayama University Hospital, Department of Gastroenterology, Okayama-city, Japan (GRID:grid.412342.2) (ISNI:0000 0004 0631 9477)
3 Okayama Saiseikai General Hospital, Department of Internal Medicine, Okayama, Japan (GRID:grid.416814.e) (ISNI:0000 0004 1772 5040)
4 Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Department of Gastroenterology and Hepatology, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472); Okayama University Hospital, Department of Gastroenterology, Okayama-city, Japan (GRID:grid.412342.2) (ISNI:0000 0004 0631 9477)